|
Clinicopathological characteristics and discrepant HER2 FISH status between primary tumour and distant metastasis |
||||||||
| Case no. |
Age (years) |
Clinicopathological characteristics |
HER2 status |
|||||
| Tumour size (cm) |
Histology |
Gradea |
Metastatic |
Metastases |
Primary tumour |
Explanationb |
||
|
|
||||||||
| 1 |
34 |
1.0 |
Ductal |
3 |
Pleura |
Amplified |
Negative |
True discrepancy |
| 2 |
52 |
Not available |
Ductal |
3 |
Cerebrospinal fluid |
Amplified |
Negative |
True discrepancy |
| 3 |
65 |
2.5 |
Ductal |
3 |
Pleura |
Amplified |
Negative |
True amplification |
| 4 |
52 |
1.6 |
Ductal |
3 |
Pleura |
Negative |
Amplified |
True amplification |
| 5 |
47 |
1.8 |
Ductal |
3 |
Ascites |
Negative |
Amplified |
Borderline |
| 6 |
47 |
Not available |
Ductal |
3 |
Pleura |
Negative |
Amplified |
True amplification |
| 7 |
82 |
5.2 |
Ductal |
2 |
Pleura |
Negative |
Amplified |
Borderline |
| 8 |
62 |
2.5 |
Ductal |
3 |
Lung |
Negative |
Amplified |
True negative |
|
HER2, gene encoding human EGF-like receptor 2; FISH, fluorescence in situ hybridization; true discrepancy, discrepancy remained unexplained; true amplification, amplification was found both in the metastasis and in the primary tumour after review; true negative, amplification was not confirmed after review; borderline, discrepancy was explained by interpretational difficulty due to a HER2/CEP17 ratio close to the threshold of 2 or less. aNuclear grade (1 to 3); bexplanations for the discrepancies of HER2 status. | ||||||||
Tapia et al. Breast Cancer Research 2007 9:R31 doi:10.1186/bcr1676 |
||||||||